Q1 2025 EPS Estimates for Dynavax Technologies Co. Increased by William Blair (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at William Blair boosted their Q1 2025 EPS estimates for shares of Dynavax Technologies in a research report issued on Tuesday, August 6th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.04 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.12 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.03 EPS.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The firm had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. During the same period last year, the firm posted $0.03 EPS.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Wednesday. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Dynavax Technologies Stock Performance

NASDAQ:DVAX traded up $0.40 during midday trading on Thursday, reaching $11.10. The stock had a trading volume of 2,976,587 shares, compared to its average volume of 2,151,702. The firm has a fifty day simple moving average of $11.20 and a two-hundred day simple moving average of $11.84. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $15.15. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36. The stock has a market cap of $1.45 billion, a P/E ratio of 185.00 and a beta of 1.28.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the sale, the director now directly owns 36,905 shares in the company, valued at approximately $440,276.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.98% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Duality Advisers LP purchased a new stake in shares of Dynavax Technologies in the 1st quarter worth about $227,000. Natixis Advisors L.P. boosted its position in shares of Dynavax Technologies by 10.5% in the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 1,804 shares in the last quarter. Executive Wealth Management LLC purchased a new stake in shares of Dynavax Technologies in the 4th quarter worth about $280,000. Boston Partners purchased a new stake in shares of Dynavax Technologies in the 1st quarter worth about $292,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Dynavax Technologies by 67.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 10,143 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.